Expert Review of Precision Medicine and Drug Development

Scope & Guideline

Empowering breakthroughs in pharmacology and genetics.

Introduction

Delve into the academic richness of Expert Review of Precision Medicine and Drug Development with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2380-8993
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2016 to 2024
AbbreviationEXPERT REV PRECIS ME / Expert Rev. Precis. Med. Drug Dev.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The 'Expert Review of Precision Medicine and Drug Development' journal aims to bridge the gap between cutting-edge research and clinical application in the realms of precision medicine and drug development. Its focus encompasses a variety of methodologies and core areas that contribute to advancing personalized healthcare solutions.
  1. Precision Oncology:
    A significant focus on the application of precision medicine in oncology, emphasizing personalized treatment strategies based on genetic and molecular profiling of tumors.
  2. Biomarker Development:
    Research dedicated to the identification and validation of biomarkers that facilitate tailored therapeutic approaches, enhancing treatment efficacy and patient outcomes.
  3. Integration of Technology in Medicine:
    Exploration of advanced technologies, including artificial intelligence and digital healthcare solutions, to improve diagnostic and therapeutic processes in precision medicine.
  4. Patient-Centric Approaches:
    A consistent emphasis on personalizing treatment based on individual patient characteristics, including genetic makeup, disease phenotype, and response to therapies.
  5. Regulatory and Clinical Trial Considerations:
    Discussion of the challenges and innovations in clinical trial design, particularly those that focus on biomarker-driven therapies and precision medicine.
The landscape of precision medicine and drug development is continually evolving, and the 'Expert Review of Precision Medicine and Drug Development' journal reflects this dynamism. Recent trends highlight emerging themes that are gaining traction among researchers.
  1. Artificial Intelligence in Precision Medicine:
    An increasing number of publications focus on the integration of artificial intelligence for drug discovery and personalized treatment planning, underscoring its transformative potential in healthcare.
  2. Immunotherapy and Personalized Approaches:
    There is a marked rise in research concerning immunotherapy tailored to individual patient profiles, particularly in oncology, reflecting its growing importance in modern treatment paradigms.
  3. Digital Health and Telemedicine Innovations:
    Emerging themes in digital healthcare approaches are becoming prominent, emphasizing the role of technology in monitoring patient outcomes and enhancing treatment personalization.
  4. Multi-Omics Approaches:
    The trend towards utilizing multi-omics data (genomics, proteomics, metabolomics) to inform precision medicine strategies is gaining momentum, allowing for more comprehensive patient profiling.
  5. Ethical and Regulatory Frameworks:
    As precision medicine advances, discussions surrounding the ethical implications and regulatory challenges are becoming more frequent, indicating a need for robust frameworks to guide implementation.

Declining or Waning

While certain areas of focus continue to thrive, some themes within the 'Expert Review of Precision Medicine and Drug Development' journal appear to be waning or receiving less attention in recent publications. This section elucidates these declining scopes.
  1. Generalized Treatment Approaches:
    There seems to be a decline in publications addressing broad or generalized treatment methodologies, with a shift towards more specific, personalized strategies.
  2. Traditional Drug Development Models:
    The journal has seen a decrease in discussions surrounding conventional drug development processes, as the trend moves towards innovative, biomarker-driven, and personalized approaches.
  3. Non-Specific Biomarker Research:
    Research focusing on non-specific biomarkers or those lacking clear clinical applicability is becoming less prominent, as the emphasis shifts to more targeted biomarker discovery.

Similar Journals

MEDICINAL RESEARCH REVIEWS

Driving Excellence in Molecular Medicine Research
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

Genome Medicine

Advancing the Frontier of Genetic Understanding
Publisher: BMCISSN: 1756-994XFrequency: 1 issue/year

Genome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.

NATURE REVIEWS DRUG DISCOVERY

Uncovering breakthroughs in drug discovery.
Publisher: NATURE PORTFOLIOISSN: 1474-1776Frequency: 12 issues/year

Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.

Cancer Biology & Medicine

Bridging Knowledge Gaps in Oncology
Publisher: CHINA ANTI-CANCER ASSOCISSN: 2095-3941Frequency: 4 issues/year

Cancer Biology & Medicine is a distinguished Open Access journal published by the China Anti-Cancer Association, dedicated to advancing research and understanding in the fields of Cancer Research and Oncology. Since its inception in 2012, the journal has provided a vital platform for the dissemination of high-quality research, evidenced by its impressive ranking within the Q1 and Q2 categories of oncology and cancer research as of 2023. With a significant impact factor and a Scopus ranking of #64 in Medicine/Oncology and #55 in Biochemistry, Genetics, and Molecular Biology, it plays a crucial role in shaping the future of cancer biology. By offering open access to its content, the journal ensures that pivotal research findings are readily available to researchers, professionals, and students globally, thereby fostering collaboration and innovation in cancer research. Situated in Tianjin, China, this journal is poised at the frontier of oncology research, making a significant impact through its rigorous peer-reviewed articles that address critical challenges in the field.

Precision and Future Medicine

Pioneering research for a personalized medical landscape.
Publisher: SUNGKYUNKWAN UNIV SCH MEDICINEISSN: 2508-7940Frequency: 4 issues/year

Precision and Future Medicine is an esteemed academic journal published by Sungkyunkwan University School of Medicine, dedicated to advancing the fields of precision medicine and healthcare innovation. Established as an Open Access journal in 2017, it aims to disseminate cutting-edge research and insights that bridge the gap between basic and clinical sciences. With a focus on personalized medicine, genomics, and advanced therapeutic strategies, the journal serves as a vital resource for researchers, clinicians, and policy makers. Set in the dynamic environment of South Korea, Precision and Future Medicine provides a platform for the exchange of ideas that are shaping the future of medical science, thus contributing significantly to the global dialogue on health and wellness. As it continues to grow, the journal is committed to ensuring that high-quality research remains accessible to all, fostering a spirit of collaboration and innovation within the scientific community.

Pharmaceutical Medicine

Connecting researchers to shape the future of pharmaceutical sciences.
Publisher: SPRINGER INT PUBL AGISSN: 1178-2595Frequency: 6 issues/year

Pharmaceutical Medicine is a leading journal published by SPRINGER INT PUBL AG, dedicated to the field of pharmacology and pharmaceutical sciences. With ISSN 1178-2595 and E-ISSN 1179-1993, this journal serves as an essential platform for researchers and professionals to share groundbreaking findings and advancements in medication efficacy, safety, and innovative therapeutic strategies. Recognized for its contribution to the field, Pharmaceutical Medicine holds an impressive Q2 ranking in both Pharmacology and Medical Pharmacology categories, further underscored by its competitive Scopus rankings—positioned at 100/272 (63rd percentile) in Medical Pharmacology and 156/313 (50th percentile) in Pharmacology, Toxicology, and Pharmaceutics. Although it primarily operates on a traditional subscription basis, its robust academic reputation continues to attract a diverse readership worldwide. Addressed in the United Kingdom with facilities in Switzerland, the journal publishes authoritative articles from its inception in 2000 through to 2024, making it a pivotal resource for those seeking to enhance their understanding and application of pharmacological principles in clinical practice and research.

Molecular Diagnosis & Therapy

Catalyzing Breakthroughs in Diagnosis and Therapy
Publisher: ADIS INT LTDISSN: 1177-1062Frequency: 6 issues/year

Molecular Diagnosis & Therapy, published by ADIS INT LTD, is a premier journal dedicated to the cutting-edge fields of genetics, molecular medicine, and pharmacology. With a strong emphasis on the translation of molecular insights into innovative therapeutic strategies, this journal serves as a vital resource for researchers, clinicians, and students aiming to stay at the forefront of medical and scientific advancements. The journal boasts an impressive standing in its categories, holding a Q1 ranking in Genetics, Medicine (miscellaneous), and Pharmacology, alongside a Q2 classification in Molecular Medicine for 2023, reflecting its influential contributions to the scientific community. Indexed in Scopus, it occupies distinct positions in its respective fields, ranked #77 in Genetics and Pharmacology, and #53 in Molecular Medicine, highlighting its robust impact factor and scholarly influence. Although it is not open access, the journal ensures widespread dissemination of valuable research, promoting enhanced understanding of molecular diagnostic techniques and therapeutic interventions. Since its inception in 2001, and continuing through to 2024, Molecular Diagnosis & Therapy remains an essential platform for disseminating vital research findings, fostering academic collaboration, and driving forward the dialogue in molecular diagnostics and treatment methodologies.

Targeted Oncology

Advancing cancer care through targeted research.
Publisher: SPRINGERISSN: 1776-2596Frequency: 6 issues/year

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

Circulation-Genomic and Precision Medicine

Bridging Genomics and Cardiovascular Health
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2574-8300Frequency: 6 issues/year

Circulation-Genomic and Precision Medicine is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, dedicated to advancing the fields of cardiology, cardiovascular medicine, and genetics. With an impressive impact factor and ranked in the Q1 quartile across multiple categories, including Cardiology and Genetics, this journal is pivotal for researchers and professionals seeking the latest insights and advancements in precision medicine. Established in 2018, it has rapidly gained recognition, evidenced by its commendable Scopus ranking and high percentiles among related fields. The journal emphasizes open access to enhance the dissemination of knowledge, making cutting-edge research readily available to a global audience. With the convergence of genomic science and cardiovascular health, Circulation-Genomic and Precision Medicine aims to foster interdisciplinary collaborations, offering a vital platform for innovative studies that impact patient care and clinical practices.

Annual Review of Pathology-Mechanisms of Disease

Charting New Territories in Pathophysiological Insights
Publisher: ANNUAL REVIEWSISSN: 1553-4006Frequency: 1 issue/year

Annual Review of Pathology: Mechanisms of Disease is a premier scholarly journal published by ANNUAL REVIEWS that systematically reviews significant advancements in the field of pathology and the mechanisms underpinning various diseases. With an ISSN of 1553-4006 and an E-ISSN of 1553-4014, the journal has established its importance within the academic community, evidenced by its prestigious Q1 rankings in several categories including medicine, pathology, forensic medicine, and plant science for 2023. Notably, it ranks #1 out of 208 in the pathology and forensic medicine category, placing it in the 99th percentile according to Scopus metrics. Although not an open-access journal, it offers crucial insights to researchers, professionals, and students alike by providing a comprehensive understanding of pathophysiological concepts and emerging trends. The journal continues to be an essential resource for those dedicated to advancing research and practical applications in disease mechanisms.